Drug-induced liver injury (DILI) was associated with changes in gut bacteria and circulating metabolites, according to a study investigating potential biomarkers for identifying the condition and assessing its severity.
Findings suggest that combining gut microbiome and metabolomic profiles could help characterise DILI, although further research is needed before these markers can be considered for clinical use.
Investigating the Gut–Liver Axis in DILI
Researchers recruited 56 participants, comprising 33 patients with DILI and 23 healthy controls, to investigate the relationship between gut microbial composition and systemic metabolic changes. The DILI group was further divided into patients with mild disease (n=21) and moderate-to-severe disease (n=12).
Blood samples were analysed using untargeted metabolomics, while faecal samples underwent 16S ribosomal RNA sequencing. Researchers then examined associations between altered bacterial populations and circulating metabolites.
Compared with healthy controls, patients with DILI had reduced gut microbial richness and diversity, alongside differences in bacterial composition.
Metabolites Show Potential as Candidate Biomarkers
Correlation analysis identified three metabolites associated with microbial changes: glycocholic acid, carnosine, and valylphenylalanine (Val-Phe). Individual analyses showed apparent discriminatory performance, with Val-Phe achieving the highest area under the receiver operating characteristic curve (AUC) at 0.992. A combined model achieved an apparent AUC of 1.000.
Researchers also identified metabolic and microbial differences between mild and moderate-to-severe DILI. A separate model incorporating three severity-associated metabolites achieved an apparent AUC of 0.885.
Further Validation Is Needed
Findings suggest that gut microbial and metabolic changes are associated with DILI and may provide useful avenues for biomarker research. However, researchers cautioned that the apparent diagnostic performance of the combined models may reflect overfitting, given the small sample size and absence of independent validation.
Researchers concluded that these microbiota-associated metabolites represent exploratory candidate biomarkers for distinguishing DILI from healthy controls and assessing disease severity. Larger independent studies and further mechanistic research are needed to establish their diagnostic value.
Reference
Yin L et al. The landscape and interplay of gut microbiome and metabolites in drug-induced liver injury.Eur J Med Res. 2026; DOI: 10.1186/s40001-026-05407-4.